Singapore: Phylogica, a public Australian peptide drug discovery company, has achieved a research milestone under its collaboration and license agreement with Pfizer to discover novel peptide-based vaccines. This milestone follows the successful completion of the first stage of the collaboration, which was announced in December 2010.

Under the terms of the agreement, Phylogica will receive an undisclosed payment in relation to the recent milestone achievement.

Dr Paul Watt, Phylogica's chief executive officer, said, "We are excited to have reached this research milestone in our collaboration with Pfizer. Our Phylomer platform has unique capabilities to identify candidate antigens and we have identified multiple novel Phylomers that meet the criteria required for further evaluation by Pfizer. We look forward to the outcome of Pfizer's ongoing evaluation of these Phylomers and hopefully advancing a candidate towards development."